Frequently Asked Questions
In 2022, the global Oligonucleotide API Market is expected to be worth USD 2315.5 million.
The Oligonucleotide API Market is estimated to increase at a CAGR of 10.60% between 2023 and 2030, reaching USD 5184.2 Million in 2030.
Oncology is now the industry leader in the Oligonucleotide APIs market
Antisense oligonucleotides are expected to account for the majority of revenue
Rare diseases are one of the Oligonucleotide API market’s fastest-growing sectors
In 2022, North America is the largest region in the Oligonucleotide API North America dominates the Oligonucleotide API Market, accounting for around 45% of the global market share
The top players include Jazz Pharmaceuticals, Sarepta Therapeutics, Biogen, Dynavax Technologies, Akcea Therapeutics, Alnylam Pharmaceuticals
The primary drivers of the market include rising demand for personalized medicine and targeted therapies, advancements in oligonucleotide synthesis technologies and manufacturing processes, and rising investments in research & development of oligonucleotide-based therapeutics.
Stringent regulatory requirements for approval of oligonucleotide-based drugs, High manufacturing costs associated with oligonucleotide APIs and Limited awareness and understanding of oligonucleotide-based therapies among healthcare professionals and patients are the key restraints of the market
Expansion of applications beyond traditional therapeutic areas, Collaborations and partnerships between pharmaceutical companies and research institutions and Emerging markets and untapped potential for oligonucleotide-based therapies in developing countries are the key opportunities in the market